- A clinically validated framework for auditing AI chatbot behavior in mental health interactions
Nature Medicine, Published online: 07 August 2026; doi:10.1038/s41591-026-04577-2Across 810 conversations, an evaluation framework finds that AI chatbots often amplify simulated users’ psychological vulnerabilities, revealing persistent safety risks in mental health contexts.
- Large-scale whole-genome sequencing reveals the landscape and health implications of de novo mutations
Nature Medicine, Published online: 07 August 2026; doi:10.1038/s41591-026-04585-2This whole-genome sequencing study based on 7,851 parent−offspring families shows that parental age and assisted reproductive technologies influence the number and types of de novo mutations, highlighting potential health impacts and the need to optimize reproductive practices.
- Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial
Nature Medicine, Published online: 06 August 2026; doi:10.1038/s41591-026-04541-0In a publicly funded trial undertaken in the NHS in England, 60 adults with treatment-resistant major depression received psilocybin or placebo alongside standardized psychological support, with psilocybin showing significant improvements in depression symptoms, good tolerability and support for further research in public healthcare settings.
- Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial
Nature Medicine, Published online: 06 August 2026; doi:10.1038/s41591-026-04557-6In this phase 1 dose-escalation trial, intracranial delivery of B7-H3-targeting chimeric antigen receptor T cell therapy in patients with glioblastoma showed no dose-limiting toxicity signals and encouraging signals of clinical benefit.
- Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial
Nature Medicine, Published online: 05 August 2026; doi:10.1038/s41591-026-04546-9A randomized controlled trial found that dronabinol significantly reduced both the frequency and intensity of nightmares in patients with PTSD over 10 weeks, compared with placebo.
- Divergent impacts of explainable AI for dermatological diagnosis on clinicians versus lay people
Nature Medicine, Published online: 04 August 2026; doi:10.1038/s41591-026-04553-wExplainable AI, implemented for large language models that assist with dermatological diagnoses, has differing effects depending on whether the assistance is provided to primary care physicians or to lay users.
- The next generation of antibody–drug conjugates
Nature Medicine, Published online: 03 August 2026; doi:10.1038/s41591-026-04543-yThe authors outline strategies to maximize the impact of ADCs by integrating multiple chemistry advances into drug constructs, and developing infrastructures and tools to accelerate and de-risk the preclinical and early clinical development of these agents.
- Non-invasive tests for the evaluation of liver fibrosis in MASLD
Nature Medicine, Published online: 03 August 2026; doi:10.1038/s41591-026-04560-xIn the LITMUS imaging study, we assessed non-invasive alternatives to liver biopsy histopathology in metabolic dysfunction-associated steatotic liver disease (MASLD). Elastography and elastography-based composite scores had sufficient diagnostic accuracy to replace liver biopsy histopathology in evaluating advanced fibrosis and cirrhosis, but no markers were accurate enough for diagnosing metabolic dysfunction-associated steatohepatitis (MASH).